Conditions: Relapsing-remitting Multiple Sclerosis
Keywords: fingolimod Biomarker Multiple sclerosis Relapsing-remitting multiple sclerosis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 133
Healthy volunteers: no

Brief summary:
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod. Long-term changes in T cell counts will be compared to short-term changes in immune status (baseline to month 6) after treatment start with fingolimod as assessed in the original Biobank study (CFTY720DDE01).

Detailed description:

Arms:
arm 1: Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).

Interventions: intervention 1: fingolimod
Intervention descriptions: intervention 1: None

Protocol document: